Ibogaine Therapy Consent Forms — What They Must Say

Every clinic offering ibogaine therapy will hand you something to sign. It might be two pages or twenty, sent weeks in advance or produced on arrival, written by a physician or copied from a liability waiver. The document is rarely discussed, yet it tells you more about how a clinic thinks than its website does. This ibogaine treatment guide is independent of any provider, so this article can say plainly what an informed consent form for ibogaine therapy should contain, why the bar is different from a hospital consent form, and what the gaps reveal.

Why ibogaine therapy consent is not like a hospital consent form

In regulated medicine, consent forms are shaped by decades of case law, professional standards and institutional review. In the United States, research consent follows the Common Rule, codified at 45 CFR 46.116, which lists the basic elements every form must include: the purpose and procedures, reasonably foreseeable risks, expected benefits, alternatives, confidentiality protections, whom to contact, and a clear statement that participation is voluntary. Hospital treatment consent draws on the same principles.

Ibogaine sits outside that machinery. It is a Schedule I controlled substance in the United States and is not approved by the FDA for any indication. Most treatment happens in Mexico, where ibogaine is not scheduled, and a small amount in countries such as New Zealand, where it is a prescription medicine.

No regulator reviews a Mexican clinic's consent form. No ethics board approves it. The clinic writes whatever it wants, and the market has produced everything from careful medical documents to single-paragraph waivers.

The contrast with other psychedelic-assisted treatments is instructive. MDMA-assisted therapy for PTSD moved through FDA-regulated Phase 3 trials, with consent documents approved by institutional review boards, before the FDA declined to approve it in 2024. Whatever the outcome, the consent infrastructure existed. Our comparison of ibogaine vs MDMA therapy covers the differences in evidence and regulation in more depth.

State-funded ibogaine research, such as the initiative in Texas, may eventually build similar infrastructure for trials. It does not change what a private clinic hands you today.

That leaves the Common Rule as something useful: a benchmark you can hold a clinic to voluntarily. A clinic is not legally required to meet it. A clinic that chooses to is telling you something.

What a real ibogaine therapy consent form must say

A genuine informed consent form for ibogaine therapy is a description of the treatment, written for a layperson, that would let a stranger understand what is about to happen and why it might go wrong. Here is what it should cover.

The substance itself

Which form is being given: ibogaine hydrochloride, a total alkaloid extract, or iboga root bark. Where it is sourced and whether purity is tested. These are different products with different predictability, and a form that only says "ibogaine" has skipped the first question. If the terminology is new to you, start with our explainer on what is ibogaine.

The dose and how it is set

Weight-based dosing is the norm, adjusted for medical findings. The form should say how the dose is determined, whether a test dose precedes the full dose, and who has the authority to reduce or cancel it.

The cardiac risk, in plain words

Ibogaine prolongs the QT interval and slows the heart. People have died. A 2012 review by Alper and colleagues in the Journal of Forensic Sciences examined nineteen fatalities temporally associated with ibogaine between 1990 and 2008, and identified pre-existing medical conditions, particularly cardiovascular ones, or other drugs taken alongside ibogaine in most of the cases where records allowed. A consent form that uses the word "complications" where it should use the word "death" is not informing you.

Other foreseeable effects

Nausea and vomiting, ataxia that can last a day or more, insomnia, intense and sometimes distressing psychological material, and the possibility of no subjective effect at all. Honest forms list these without minimizing them.

Medication and withdrawal handling

Which of your current medications will be stopped, when, and on whose authority. How long-acting opioids such as methadone or buprenorphine are handled before treatment, since most programs require a switch to short-acting opioids first. How alcohol or benzodiazepine dependence, with its own seizure risk, changes the plan.

Screening and exclusion

The tests that will be run, at minimum an ECG, electrolytes, liver function and, where relevant, a pregnancy test, and the results that would cancel treatment. The form should also say what happens financially if screening excludes you after you have travelled.

Monitoring and the emergency plan

Whether cardiac monitoring is continuous through the acute phase. Who is physically present, and their qualifications. Whether advanced life support, a defibrillator and intravenous access are on site. The name and distance of the receiving hospital and how transfer is arranged.

Alternatives

Buprenorphine, methadone, naltrexone and conventional residential treatment exist and have evidence behind them. A consent form is supposed to acknowledge that you have other options, not pretend you do not.

Aftercare, money and confidentiality

What follow-up is included and who is responsible for it. The total cost, the deposit rules and what is refundable. How your records are stored and whether your image or story may be used in marketing without separate permission.

Voluntariness and signatures

A statement that you may withdraw at any point before dosing, with any penalty stated rather than implied. A date, a witness, and a copy for you to keep.

Red flags: what the wording, or the silence, tells you

Reading a consent form critically is faster than it sounds. A handful of patterns separate documents written to inform from documents written to protect the clinic.

• No mention of cardiac risk or death. The single most important risk is missing. Nothing else in the document can compensate.
• Outcome language. Success rates, "cure," or promises about cravings do not belong in a consent form. Their presence means the document is marketing.
• "Natural, therefore safe." Iboga is a plant. So is foxglove. The argument is a warning sign.
• A waiver with no risk description. Releasing a clinic from liability is not the same as understanding what you are consenting to. A waiver can accompany consent; it cannot replace it.
• No named responsible clinician. Forms that name a "facilitator" or "team" but no physician leave the question of medical authority unanswered.
• A hospital that is "nearby." Real emergency plans name the facility and the drive time.
• Refusal to send it in advance. If you cannot read the form until you arrive, the clinic has decided when you are allowed to think about it.

None of these alone proves a clinic is dangerous. Together they describe one that has not thought of itself as a medical provider, and the consent form is where that shows first.

Can you give informed consent while in withdrawal?

This question deserves its own section because it is the one most clinics avoid. Consent requires capacity: the ability to understand information, appreciate how it applies to you, reason about it, and communicate a choice. Acute opioid withdrawal impairs concentration and sleep, and craving distorts how risk is weighed. A person on day two of withdrawal, in an unfamiliar country, signing a document they have never seen, is not in a strong position to consent to anything.

The ethical fix is process rather than paperwork. The form should be sent weeks ahead. Someone qualified should walk through it by phone or video, and you should be able to ask questions and get answers in writing. A support person you trust should be able to read it.

On the day, consent should be reaffirmed when you are stable enough to engage, and that reaffirmation should be documented. Clinics that do this are not slower; they are simply treating consent as something that happens over time rather than in a signature.

If you are the family member of someone considering ibogaine therapy, ask to see the form yourself. A clinic that resists a family member reading a consent document has told you how it regards outside scrutiny.

Questions to ask before you sign

Bring these to the clinic in writing and keep the answers.

1. Can you send me the full consent form now, before I pay a deposit?
2. Which physician is medically responsible for me during the acute phase, and what are their credentials?
3. What specific findings on my ECG or labs would cancel treatment, and what is refunded if that happens?
4. Is cardiac monitoring continuous, and who is watching it at three in the morning?
5. Which hospital would I be taken to, and how far is it?
6. How and when will consent be reviewed with me again once I arrive?
7. May my spouse, parent or friend read the form and join the pre-treatment call?

A consent form cannot make ibogaine therapy safe. It cannot lower a QT interval or replete potassium. What it can do is show you, before you have spent a dollar or boarded a flight, whether the people you are about to trust with your heart have thought carefully about the ways it could stop. For neutral, clinic-independent information on screening, safety and what to expect, the rest of this Ibogaine Treatment Guide is written to help you make that judgment on your own terms.

This article is educational and is not medical or legal advice. Ibogaine carries serious cardiac risks; decisions about treatment should be made with a qualified physician who knows your history.